Publication date: Jan 10, 2025
Coronavirus disease 2019 (COVID-19) poses significant risks for solid organ transplant recipients, who have atypical but poorly characterized immune responses to infection. We aim to understand the host immunologic and microbial features of COVID-19 in transplant recipients by leveraging a prospective multicenter cohort of 86 transplant recipients age- and sex-matched with 172 non-transplant controls. We find that transplant recipients have higher nasal SARS-CoV-2 viral abundance and impaired viral clearance, and lower anti-spike IgG levels. In addition, transplant recipients exhibit decreased plasmablasts and transitional B cells, and increased senescent T cells. Blood and nasal transcriptional profiling demonstrate unexpected upregulation of innate immune signaling pathways and increased levels of several proinflammatory serum chemokines. Severe disease in transplant recipients, however, is characterized by a less robust induction of pro-inflammatory genes and chemokines. Together, our study reveals distinct immune features and altered viral dynamics in solid organ transplant recipients.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | IDO | host |
disease | MESH | COVID-19 |
disease | MESH | infection |
disease | IDO | blood |
disease | IDO | cell |
drug | DRUGBANK | Tacrolimus |
drug | DRUGBANK | Mycophenolate mofetil |
disease | IDO | protein |
disease | IDO | susceptibility |
drug | DRUGBANK | Isoxaflutole |
drug | DRUGBANK | Trestolone |
disease | MESH | viral infections |
drug | DRUGBANK | Aspartame |
drug | DRUGBANK | Cysteamine |
drug | DRUGBANK | Mycophenolic acid |
drug | DRUGBANK | Serine |
disease | IDO | assay |
disease | IDO | symptom |
disease | MESH | functional status |